Mark Samuels on Open Innovation in Pharma

The Pharma Times Online website posted an interview with Mark Samuels, chief business and strategy officer of the new Medicines Discovery Catapult, on the role of open innovation in big pharma: “I think collaborative research is increasingly important. Benefits of open innovation include access to knowledge outside the firm, as well as being able to draw on the best expertise to deliver research – even when that expertise resides outside the firm. However, companies that had historically done most of the R&D internally face difficult changes to embrace open innovation. Open innovation requires significant cultural change. Working in a highly collaborative manner is a big change for many companies and cultural change is traditionally very difficult. However, I’m hopeful that the need to develop new medicines will catalyze open innovation, resulting in increased R&D productivity.”

Click here to read the full article.
.
Image via Flickr.